Budenofalk rectal foam for ulcerative colitis

Dr Falk has launched Budenofalk (2mg budesonide) rectal foam, indicated for treatment of active ulcerative colitis limited to the rectum and sigmoid colon.

The new presentation is available as a canister containing 14 days’ treatment of budesonide foam (2mg per actuation). The recommended dosage for adults over 18 years is one actuation daily.

Treatment with Budenofalk rectal foam results in lower systemic steroid levels than oral therapy with systemic steroids. Transfer from other steroid therapy may result in symptoms relating to the change in systemic steroid levels.

Budenofalk is also available as 3mg capsules indicated for mild to moderate Crohn’s disease affecting the ileum and/or ascending colon and symptomatic relief of chronic diarrhoea due to collagenous colitis.

Further information: Dr Falk 01628 536600

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more